Health × Macro
Eli Lilly's oral GLP-1 'orforglipron' wins FDA approval
Eli Lilly cleared orforglipron, a once-daily oral GLP-1 receptor agonist, on April 1. It is the first small-molecule GLP-1 for chronic weight loss in obese or overweight patients, with a starting dose of 0.8mg.
Primary sources · 2